跳转至内容
Merck
CN

主要文件

查看所有文档

K1003

酮康唑

99.0-101.0% (EP, titration), meets EP testing specifications

别名:

(±)-顺-1-乙酰基-4-(4-[(2-[2,4-二氯苯基]-2-[1H-咪唑-1-基甲基]-1,3-二氧戊环-4-基)-甲氧基]苯基)哌嗪

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C26H28Cl2N4O4
化学文摘社编号:
65277-42-1
分子量:
531.43
NACRES:
NA.85
PubChem Substance ID:
24278176
UNSPSC Code:
51101500
EC Number:
265-667-4
MDL number:
MFCD00058579
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Quality Level

200

agency

meets EP testing specifications

description

Specific Optical Rotation (EP): (−0.10) ∼ +0.10 °

assay

99.0-101.0% (EP, titration)

form

powder

color

white to off-white

antibiotic activity spectrum

Gram-positive bacteria, fungi, yeast

mode of action

enzyme | inhibits

storage temp.

2-8°C

SMILES string

CC(=O)N1CCN(CC1)c2ccc(OC[C@H]3CO[C@@](Cn4ccnc4)(O3)c5ccc(Cl)cc5Cl)cc2

InChI

1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1

InChI key

XMAYWYJOQHXEEK-OZXSUGGESA-N

Gene Information

human ... ABCB1(5243), CYP11B1(1584), CYP11B2(1585), CYP17A1(1586), CYP19A1(1588), CYP1A2(1544), CYP24A1(1591), CYP26A1(1592), CYP3A4(1576), CYP51A1(1595), KCNH1(3756)
mouse ... Abcb1a(18671), Abcb1b(18669)
rat ... Alox5(25290), Cyp17a1(25146), Cyp51(25427), Cyp7a1(25428)

General description

化学结构：咪唑

Application

CYP3A4抑制剂
酮康唑是一种广谱抗真菌药，可用于治疗念珠菌病、慢性粘膜皮肤念珠菌病、口腔鹅口疮、念珠菌、芽生菌病、球孢子菌病、组织胞浆菌病、色素霉菌病和副球菌病。 它被用于鉴定猴模型中p-糖蛋白/CYP3A限制的生物利用度，研究白细胞介素1介导的抗肿瘤作用以及 体内药物相互作用

Biochem/physiol Actions

抗真菌剂
酮康唑能够与14-α去甲基化酶发生相互作用，这是一种细胞色素P-450酶，是羊毛甾醇转化为麦角甾醇所必需的酶。这种相互作用抑制了麦角甾醇合成并导致真菌细胞渗透性增强。其他可能的作用机制是抑制内源性呼吸、与膜磷脂的相互作用、抑制酵母转化为菌丝体形式、抑制嘌呤摄取以及破坏甘油三酯和/或磷脂生物合成。酮康唑可抑制血栓素和甾醇的合成，如醛固酮、皮质醇和睾酮。

Still not finding the right product?

Explore all of our products under 酮康唑

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B - STOT RE 2

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
SLCC4160
SLBR1290V
SLBK7327V
SLBG3774V
SLBB5223V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Wendy W J van de Sande et al.
Antimicrobial agents and chemotherapy, 54(6), 2738-2740 (2010-03-31)
Eumycetoma caused by Madurella mycetomatis is treated surgically and with high doses of ketoconazole. Therapeutic responses are poor, and recurrent infections are common. In search of therapeutic alternatives in the treatment of mycetoma, we determined the in vitro susceptibilities of
Francisco M Garibotto et al.
Bioorganic & medicinal chemistry, 18(1), 158-167 (2009-12-05)
The synthesis, in vitro evaluation, and conformational study of a new series of small-size peptides acting as antifungal agents are reported. In a first step of our study we performed a conformational analysis using Molecular Mechanics calculations. The electronic study
L L von Moltke et al.
The Journal of pharmacology and experimental therapeutics, 268(3), 1278-1283 (1994-03-01)
Biotransformation of the tricyclic antidepressant desipramine (DMI) to its metabolite 2-hydroxy-desipramine (2-OH-DMI) was studied in vitro using microsomal preparations from human, monkey, mouse and rat liver. In all species 2-OH-DMI was the principal identified metabolite. Mean (+/- S.E.) reaction parameters
查看所有相关文献

全球贸易项目编号

货号GTIN
K1003-100MG04061833867877